Unprecedented In Vivo Retinal Imaging Achieved in Occuity’s Reading Labs

Last week Occuity marked a major milestone within Dr Alistair Bounds’ Future Leaders Fellowship with a world first, as new methods of imaging the eye were successfully deployed in vivo right here in our labs in Reading. Although most of the details are under strict lock and key as patent applications are prepared, the project has achieved a world-first in how the retina is imaged, allowing different molecules in the retina to be distinguished in vivo to an unprecedented degree and offering new insights into disease processes and pathology.

“Getting to in vivo data-taking with such brand-new methods is very exciting and evidences a major de-risking in the technology development.

These systems are already generating significant clinical interest, with potential clinical studies into both ophthalmic and oculomics conditions from age-related macular degeneration to dementia being proposed from 2027. The more immediate next steps are to continue improving the system and evidencing the safety and efficacy of the system before these trials, building on Occuity’s in-house capabilities.

Dr Alistair Bounds had this to say about the development:

“Getting to in vivo data-taking with such brand-new methods is very exciting and evidences a major de-risking in the technology development. There is still plenty to do before we get to the levels of widespread clinical impact we want to see from this system, but it shows that we are on the right direction and helps get our clinical partners even more excited by what these instruments can do!”

CEO Dan Daly also commented on the project progress:

“The work being undertaken in this project is truly groundbreaking and has the potential to fundamentally change how we screen for and prevent a whole range of both ocular and systemic diseases. In the fullness of time I’d like to see these systems used in every optician practice as we are now seeing with OCT”.

---

Do not invest unless you are prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 minutes to learn more:

Occuity is currently riasing on Republic. Invest now form as little as £30 per share.

👉 Invest in Occuity today: https://europe.republic.com/occuity2

---